Patents by Inventor Walter F. Lima

Walter F. Lima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGOMERIC COMPOUNDS AND METHODS
    Publication number: 20110313019
    Abstract: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.
    Type: Application
    Filed: October 23, 2009
    Publication date: December 22, 2011
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Eric E. Swayze, Balkrishen Bhat, Walter F. Lima, Thazha P. Prakash, Garth A. Kinberger
  • METHODS OF DETERMINING POTENCY OF CHEMICALLY-SYNTHESIZED OLIGONUCLEOTIDES
    Publication number: 20100267149
    Abstract: Provided herein are methods for determining potency of RNAi agents. Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2.
    Type: Application
    Filed: October 18, 2007
    Publication date: October 21, 2010
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Walter F. Lima, Timothy Vickers, Stanley T. Crooke
  • COMPOUNDS AND METHODS FOR MODULATING PROTEIN EXPRESSION
    Publication number: 20100093836
    Abstract: The present invention includes compositions and methods useful for modulating protein expression. In certain embodiments, the present invention includes oligomeric compounds comprising modified nucleosides and modified internucleoside linkages.
    Type: Application
    Filed: January 29, 2008
    Publication date: April 15, 2010
    Applicant: ISIS Pharmaceuticals, Inc
    Inventors: Balkrishen Bhat, Eric E. Swayze, Walter F. Lima, Stanley T. Crooke
  • Compositions and Methods For Optimizing Cleavage of Rna By Rnase H
    Publication number: 20080207541
    Abstract: The present invention provides compositions and methods for the optimization of cleavage of RNA species by RNase H. In some embodiments, the invention provides oligonucleotides that possess two or more regions of differing conformation, and at least one transitional nucleobase positioned between the regions that is capable of modulating transfer of the helical conformation characteristic of the region bound to the 3?hydroxy thereof, to the region bound to the 5? hydroxyl thereof.
    Type: Application
    Filed: March 15, 2005
    Publication date: August 28, 2008
    Inventors: Michael T. Migawa, Walter F. Lima, Eric E. Swayze, Joshua Nichols, Hongjiang Wu, Thazha P. Prakash, Tadeusz Krzysztof Wyrzykiewicz, Balkrishen Bhat, Stanley T. Crooke
  • Human RNase H1 mutants
    Patent number: 6855530
    Abstract: A human RNase H polypeptide and methods of use are provided.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: February 15, 2005
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Hongjiang Wu, Walter F. Lima, Stanley T. Crooke
  • Methods of using mammalian RNase H and compositions thereof
    Publication number: 20040248145
    Abstract: The present invention relates to methods for using mammalian RNase H, including human RNase H, and compositions thereof, particularly for reduction of a selected cellular RNA target via antisense technology. Methods and uses for increasing or decreasing RNase H levels and activity in cells and animals are disclosed.
    Type: Application
    Filed: October 6, 2003
    Publication date: December 9, 2004
    Inventors: Stanley T. Crooke, Walter F. Lima, Hongjiang Wu
  • Human RNase H1 and oligonucleotide compositions thereof
    Publication number: 20040102618
    Abstract: The present invention provides oligonucleotides that can serve as substrates for human Type 2 RNase H. The present invention is also directed to methods of using these oligonucleotides in enhancing antisense oligonucleotide therapies.
    Type: Application
    Filed: July 8, 2003
    Publication date: May 27, 2004
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Walter F. Lima, Hongjiang Wu
  • Human Rnase H1 and oligonucleotide compositions thereof
    Patent number: 6617442
    Abstract: The present invention provides oligonucleotides that can serve as substrates for human Type 2 RNase H. The present invention is also directed to methods of using these oligonucleotides in enhancing antisense oligonucleotide therapies.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: September 9, 2003
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Walter F. Lima, Hongjiang Wu, Muthiah Monoharan
  • Human RNase H1 mutants
    Publication number: 20020160486
    Abstract: A human RNase H polypeptide and methods of use are provided.
    Type: Application
    Filed: November 14, 2001
    Publication date: October 31, 2002
    Inventors: Hongjiang Wu, Walter F. Lima, Stanley T. Crooke
  • Human RNase H and compositions and uses thereof
    Publication number: 20020110892
    Abstract: The present invention provides polynucleotides and polypeptides encoded thereby of human Type 2 RNase H. Methods of using these polynucleotides and polypeptides in enhancing antisense oligonucleotide therapies are also provided.
    Type: Application
    Filed: October 22, 2001
    Publication date: August 15, 2002
    Inventors: Stanley T. Crooke, Walter F. Lima, Hongjiang Wu
  • Compositions and methods for treatment of Hepatitis C virus-associated diseases
    Patent number: 6423489
    Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: July 23, 2002
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Kazuya Hoshiko, Chikateru Nozaki, Tsukasa Nishihara, Hiroshi Nakatake, Fukusaburo Hamada, Tatsuo Eto, Shinichi Furukawa, Shoji Furusako, Thomas W. Bruice, Walter F. Lima
  • Compositions and methods for treatment of Hepatitis C virus-associated diseases
    Patent number: 6391542
    Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: May 21, 2002
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Kazuya Hoshiko, Chikateru Nozaki, Tsukasa Nishihara, Hiroshi Nakatake, Fukusaburo Hamada, Tatsuo Eto, Shinichi Furukawa, Shoji Furasako, Thomas W. Bruice, Walter F. Lima
  • Human RNase H and compositions and uses thereof
    Patent number: 6376661
    Abstract: The present invention provides polynucleotides and polypeptides encoded thereby of human Type 2 RNase H. Methods of using these polynucleotides and polypeptides in enhancing antisense oligonucleotide therapies are also provided.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: April 23, 2002
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Walter F. Lima, Hongjiang Wu
  • Determination of oligonucleotides for therapeutics, diagnostics and research reagents
    Patent number: 6022691
    Abstract: Oligonucleotides which selectively bind to target biomolecules are determined by in vitro assay of a pool of random oligonucleotides for activity against the biomolecules, followed by recovery and characterization of selected oligonucleotides. Oligonucleotides so determined may be utilized for therapeutic, diagnostic and research reagent purposes.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: February 8, 2000
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Thomas W. Bruice, Walter F. Lima
  • Human type 2 RNase H
    Patent number: 6001653
    Abstract: The present invention provides polynucleotides and polypeptides encoded thereby of human Type 2 RNase H. Methods of using these polynucleotides and polypeptides in enhancing antisense oligonucleotide therapies are also provided.
    Type: Grant
    Filed: December 2, 1998
    Date of Patent: December 14, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Stanley T. Crooke, Walter F. Lima, Hongjiang Wu
  • Determination of oligonucleotides for therapeutics, diagnostics and research reagents
    Patent number: 5686242
    Abstract: Oligonucleotides which selectively bind to target biomolecules are determined by in vitro assay of a pool of random oligonucleotides for activity against said biomolecules, followed by recovery and characterization of selected oligonucleotides. Oligonucleotides so determined may be utilized for therapeutic, diagnostic and research reagent purposes.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: November 11, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Thomas W. Bruice, Walter F. Lima